Daily Stock Analysis, ADMA, ADMA Biologics Inc, priceseries

ADMA Biologics Inc. Daily Stock Analysis
Stock Information
Open
3.95
Close
3.89
High
3.96
Low
3.85
Previous Close
3.94
Daily Price Gain
-0.05
YTD High
4.95
YTD High Date
Feb 12, 2018
YTD Low
3.13
YTD Low Date
Jan 4, 2018
YTD Price Change
0.59
YTD Gain
17.88%
52 Week High
5.44
52 Week High Date
Apr 4, 2017
52 Week Low
2.01
52 Week Low Date
Nov 6, 2017
52 Week Price Change
-1.05
52 Week Gain
-21.26%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Nov 13. 2017
2.48
Nov 29. 2017
2.98
11 Trading Days
20.32%
Link
LONG
Dec 22. 2017
2.64
Jan 31. 2018
3.64
25 Trading Days
37.88%
Link
Company Information
Stock Symbol
ADMA
Exchange
NasdaqCM
Company URL
http://www.admabiologics.com
Company Phone
(201) 478-5552
CEO
Adam S. Grossman
Headquarters
New Jersey
Business Address
C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17, RAMSEY, NJ 07446
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001368514
About

ADMA Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of human plasma and plasma-derived therapeutics. It operates through the Plasma Collection Center and Research and Development segments. The Plasma Collection Center segment comprises of operations in Georgia. The Research and Development segment involves plasma development operations in New Jersey. The company's targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Description

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. ADMA Biologics, Inc. was founded in 2004 and is based in Ramsey, New Jersey.